昂利康(002940) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥345,526,779.17, a decrease of 15.31% compared to ¥407,993,014.11 in the same period last year[4] - Net profit attributable to shareholders was ¥15,906,128.54, down 43.63% from ¥28,218,693.81 year-on-year[4] - Basic and diluted earnings per share decreased by 42.86% to ¥0.08 from ¥0.14 in the same period last year[4] - Net profit for the current period is ¥25,743,581.00, compared to ¥47,410,347.34 in the previous period, indicating a decline of approximately 45.5%[21] - Total operating revenue for the current period is ¥345,526,779.17, down from ¥407,993,014.11 in the previous period, representing a decrease of approximately 15.3%[20] - Total operating costs decreased to ¥328,054,513.62 from ¥364,384,558.95, a reduction of about 10%[20] Cash Flow - The net cash flow from operating activities was ¥29,901,970.48, representing a significant decline of 81.46% from ¥161,258,174.92 in the previous year[4] - Operating cash flow for the current period is ¥29,901,970.48, a decrease of 81.5% compared to ¥161,258,174.92 in the previous period[22] - Total cash inflow from operating activities is ¥402,132,818.90, down 12.8% from ¥461,825,250.09 year-over-year[22] - Cash outflow from operating activities increased to ¥372,230,848.42, compared to ¥300,567,075.17 in the previous period, representing a 23.9% increase[22] - Net cash flow from financing activities increased by 58.75% to ¥19,006,130.22, mainly due to new loans obtained during the period[13] - Cash inflow from financing activities totaled ¥140,450,000.00, up from ¥118,414,427.89 in the previous period, marking an increase of 18.6%[23] - The ending balance of cash and cash equivalents is ¥344,396,726.59, down from ¥971,924,461.13 in the previous period, a decrease of 64.6%[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,918,389,809.54, a decrease of 1.89% from ¥2,974,532,155.08 at the end of the previous year[4] - Total liabilities decreased to ¥1,112,302,793.08 from ¥1,176,112,275.01, a decline of approximately 5.5%[19] - Total equity increased to ¥1,806,087,016.46 from ¥1,798,419,880.07, reflecting a growth of about 0.4%[19] - Cash and cash equivalents in current assets decreased to ¥1,445,696,715.01 from ¥1,498,867,441.24, a decline of approximately 3.5%[19] - Long-term equity investments slightly decreased to ¥246,451,828.79 from ¥249,050,486.56, a reduction of about 1.0%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,266[14] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., holds 35.44% of shares, totaling 71,485,000 shares[14] - The company repurchased 4,840,000 shares, representing 2.40% of the total share capital[15] Investments and Other Activities - The company reported a 142.89% increase in trading financial assets, totaling ¥87,540,986.58 due to increased investment in financial products[10] - Accounts receivable decreased by 32.06% to ¥128,082,542.63, primarily due to improved collection of receivables[10] - The company has reduced its stake in Zhejiang Haichang Biological Technology Co., Ltd. from 5.6201% to 5.2443% after waiving its preemptive rights in a capital increase[16] - The company plans to increase the registered capital of Zhejiang Anglikang Animal Health Technology Co., Ltd. by ¥10 million, raising its total capital from ¥40 million to ¥50 million[15] Inventory and Prepayments - The company's inventory stands at ¥464,381,523.49, a decrease from ¥503,792,116.03 at the beginning of the period[17] - The company's accounts receivable decreased to ¥128,082,542.63 from ¥188,526,737.92[17] - The company’s trading financial assets increased to ¥87,540,986.58 from ¥36,040,986.58[17] - The company’s prepayments decreased to ¥11,842,507.61 from ¥16,177,618.16[17] Research and Development - Research and development expenses increased to ¥51,800,372.24 from ¥49,086,015.25, reflecting a growth of about 3.5%[21] Audit Information - The company did not undergo an audit for the first quarter report[24]